The Medical Letter on Drugs and Therapeutics
Amprenavir: A New HIV Protease Inhibitor
July 16, 1999 (Issue: 1057)Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.